Pharmaceuticals

Global Oncology Biosimilars Market Report 2026–2030: Data-Driven Growth Insights

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oncology biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Oncology Biosimilars Market size between 2026 and 2035?

The oncology biosimilars market has experienced significant expansion in recent years. This market is projected to expand from $11.35 billion in 2025 to $12.83 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. Historically, this expansion has been driven by factors such as the high expense of reference biologics, the constrained supply of oncology biosimilars, the rising global incidence of cancer, the expansion of hospital and pharmacy infrastructure, and early regulatory approvals for monoclonal antibody biosimilars.

The oncology biosimilars market is poised for substantial expansion in the upcoming years, with projections indicating a rise to $21.28 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is attributable to various factors such as the introduction of new biosimilar drugs, including pembrolizumab and pegfilgrastim, the widening scope of online pharmacy distribution networks, the increasing acceptance of immunomodulators and hematopoietic agents, elevated government initiatives aimed at improving access to cancer care, and a strengthened emphasis on personalized oncology treatment. Significant trends anticipated during this period include the growing adoption of rituximab, trastuzumab, and bevacizumab biosimilars, an expanding utilization of immunomodulators and hematopoietic agents in cancer therapy, the increasing presence of g-csf biosimilars for neutropenia management, the broadening of hospital and retail pharmacy channels for oncology biosimilars, and a sustained focus on developing cost-effective and accessible cancer treatment options.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2821&type=smp

Which Drivers Are Impacting Market Performance In The Oncology Biosimilars Market?

The emergence of novel oncology biosimilars is being propelled by the conclusion of patent protection for cancer-treating biologics. As biologics possess patents for a specific duration, their patent expiry facilitates the creation of new biosimilars. These biologics are targeted medications derived from living organisms, designed to stimulate the immune system to combat cancer cells. While not identical, biosimilars bear a strong resemblance to biologics, delivering comparable efficacy at a lower price point. A notable example is provided by DrugTimes, a Chinese pharmaceutical and biotech firm, which reported in February 2024 that over 25 products are projected to lose their patent exclusivity by 2037. This could lead to a cumulative revenue decrease surpassing $236.4 billion, calculated from 2024 sales data. This growing number of patent expirations is anticipated to significantly increase the demand for the manufacture of novel oncology biosimilars, thereby stimulating market expansion for the oncology biosimilars sector.

Which Segments Are Contributing To The Growth Of The Oncology Biosimilars Market?

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

Which Trends Are Shaping Activity Within The Oncology Biosimilars Market?

Leading companies active in the oncology biosimilars market are prioritizing the development of innovative cancer treatments, such as targeted biologics and monoclonal antibodies, to improve treatment effectiveness, patient outcomes, and overall access to oncology care. Monoclonal antibodies (mAbs) are laboratory-engineered proteins designed to recognize and bind to specific cancer cell antigens, enabling precise targeting and immune-mediated destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, integrated with Seagen and dedicated $43 billion to strengthen its oncology portfolio. This strategic action enhances Pfizer’s presence in cancer therapeutics and accelerates the advancement of sophisticated treatments for cancer, which is a major global cause of death. The investment also highlights the increasing trend of significant capital allocation towards groundbreaking oncology biosimilars to address unfulfilled medical needs and expand worldwide access to cancer care.

Who Are The Primary Competitors In The Global Oncology Biosimilars Market?

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Oncology Biosimilars Market?

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncology Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2821&type=smp

Browse Through More Reports Similar to the Global Oncology Biosimilars Market 2026, By The Business Research Company

Biosimilar Growth Hormone Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Biosimilar Monoclonal Antibodie Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Biosimilar Therapeutic Peptide Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795